Specialist life sciences investor Casdin Capital has fully exited its position in SIONNA THERAPEUTICS INC. (SION), according to a recent quarterly disclosure. The filing, which reflects the period ending September 30, 2026, shows the firm sold its entire stake of 400,000 shares, previously valued at approximately $17.60 million.

The sale occurred during a challenging quarter for Sionna. In that same period, the clinical-stage biopharmaceutical company announced its lead drug candidate for cystic fibrosis, SION-719, had failed to meet its primary endpoint in a Phase 2a trial. This news resulted in a significant drop in the company's stock price and a subsequent corporate restructuring, which included a 46% reduction in its workforce to conserve cash.